Envista Holdings Corp (NVST)

Return on equity (ROE)

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Net income (ttm) US$ in thousands -1,118,600 -1,337,200 -1,323,900 -120,400 -100,200 190,700 216,800 212,000 243,100 255,400 300,700 343,700 340,500 363,100 305,800 122,200 33,300 -19,000
Total stockholders’ equity US$ in thousands 2,934,800 3,072,500 2,976,700 4,140,300 4,173,900 4,293,200 4,311,000 4,279,000 4,206,900 3,957,900 4,016,000 4,030,900 4,057,600 3,946,700 3,868,500 3,746,900 3,720,600 3,557,600
ROE -38.12% -43.52% -44.48% -2.91% -2.40% 4.44% 5.03% 4.95% 5.78% 6.45% 7.49% 8.53% 8.39% 9.20% 7.90% 3.26% 0.90% -0.53%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-1,118,600K ÷ $2,934,800K
= -38.12%

Envista Holdings Corp's return on equity (ROE) has fluctuated significantly over the period from September 30, 2020, to December 31, 2024. The ROE started at a negative level of -0.53% in September 2020 but gradually improved to reach 9.20% by September 30, 2021. However, the ROE began to decline after reaching its peak, ending the year at 8.39% on December 31, 2021.

In the following quarters, the ROE continued to decrease before stabilizing at around 5-7% for most of 2022 and the first half of 2023. Notably, there was a significant drop in ROE to -44.48% on June 30, 2024, and it further deteriorated to -38.12% by December 31, 2024.

The negative ROE figures towards the end of 2024 indicate that Envista Holdings Corp may be experiencing operational challenges or facing financial difficulties that are impacting its profitability and shareholder value. It is important for the company to address these issues and implement strategic measures to improve its ROE and overall financial performance.


Peer comparison

Dec 31, 2024

Company name
Symbol
ROE
Envista Holdings Corp
NVST
-38.12%
Dentsply Sirona Inc
XRAY
-15.64%